Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
Epigenomics AG Begins Trading on OTCQX® PR Newswire NEW YORK, Jan. 10, 2014 NEW YORK, Jan. 10, 2014 /PRNewswire/ -- OTC Markets Group Inc...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today announced the results of a survey...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, reports that Dr. Uri Ladabaum...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnosis company, today announced the signing of a supply...
Epigenomics AG (FWB:ECX), the cancer diagnosis company, today announced the appointment of Noel Doheny as the new Chief Executive...
Epigenomics AG (FWB:ECX), the cancer molecular diagnostics company, and QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostic company, today announced that it has concluded...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnostics company, and Predictive Biosciences, a commercial stage...
Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company’s...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.